Fusion Pharmaceuticals Inc
Change company Symbol lookup
Select an option...
FUSN Fusion Pharmaceuticals Inc
RDUS Schnitzer Steel Industries Inc
ALEC Alector Inc
LZM Lifezone Metals Ltd
LMRMF Lomiko Metals Inc
SOXL Direxion Daily Semiconductor Bull 3X Shares
OXSQ Oxford Square Capital Corp
BAER Bridger Aerospace Group Holdings Inc
CMRA Comera Life Sciences Holdings Inc
SY So-Young International Inc

Health Care : Biotechnology | Small Cap Value
Based in Canada
Company profile

Fusion Pharmaceuticals Inc. is a clinical-stage oncology company. The Company is focused on developing radiopharmaceuticals as precision medicines. It has developed its Targeted Alpha Therapies (TAT), platform to enable it to connect alpha particle emitting isotopes to various targeting molecules to selectively deliver the alpha particle payloads to tumors. The TAT platform is underpinned by its ability to radiolabel various classes of targeting molecules, its research and insights into the underlying chemistry and biology of alpha emitting radiopharmaceuticals, its differentiated capabilities in target identification, candidate generation, manufacturing and supply chain, its Fast-Clear linker technology used in conjunction with antibody-based targeting molecules, and development of imaging agents. Its clinical portfolio includes FPI-2265, FPI-1434 and FPI-2059. FPI-2265 targeting prostate specific membrane antigen for metastatic castration resistant prostate cancer in a Phase 2 trial.

Day's Change
-0.145 (-5.70%)
B/A Size
Day's High
Day's Low

Today's volume of 24,170 shares is on pace to be in-line with FUSN's 10-day average volume of 28,131 shares.


Cano Health stock rebounds with 40% pop after former director says he and others agreed 'to pursue change'

3:36 pm ET April 3, 2023 (MarketWatch)

Shares of Cano Health Inc. (CANO) were up more than 40% in afternoon trading Monday after Barry Sternlicht, a former board director, disclosed in a 13D filing with the Securities and Exchange Commission that he, two others who recently left Cano's board, and certain of their affiliates have entered into an agreement "to act together to pursue change" at the company, "including, but not limited to, the replacement of the CEO, sale of non-core assets and enhancement of shareholder value." Sternlicht, Elliot Cooperstone and Lewis Gold, who all resigned from Cano's board Thursday, have a combined voting power of about 35.7%, according to the filing. Cano Health didn't immediately respond to a MarketWatch request for comment. Sternlicht said last week that he was "extremely troubled by the poor operating decisions and performance" at Cano. The company responded with a Friday statement saying that it was "disappointed that three directors chose to resign due to what we believe is their focus solely on the short term." The shares declined more than 19% in Friday's session.

-Emily Bary

This content was created by MarketWatch, which is operated by Dow Jones & Co. MarketWatch is published independently from Dow Jones Newswires and The Wall Street Journal.


(END) Dow Jones Newswires

April 03, 2023 15:36 ET (19:36 GMT)

Copyright (c) 2023 Dow Jones & Company, Inc.

Earnings Calendar and Events Data provided by |Terms of Use| © 2023 Wall Street Horizon, Inc.

Market data accompanied by is delayed by at least 15 minutes for NASDAQ, NYSE MKT, NYSE, and options. Duration of the delay for other exchanges varies.
Market data and information provided by Morningstar.

Options are not suitable for all investors as the special risks inherent to options trading may expose investors to potentially rapid and substantial losses.
Please read Characteristics and Risks of Standard Options before investing in options.

Information and news provided by ,, , Computrade Systems, Inc., ,, and

Copyright © 2023. All rights reserved.